Experimental Study on Residual Tumor Angiogenesis after
CryoablationChun-Hua Ma&, Rong Jiang&*, Jin-Duo Li, Bin Wang, Li-Wei Sun, Yuan Lv
Abstract
Objective: To explore the mechanism and significance of tumor angiogenesis by observing changes of microvessel
density (MVD) and expression of vascular endothelial growth factor (VEGF) in residual tumor tissues
after cryoablation. Materials and Methods: A total of 18 nude mice xenograft models with transplanted lung
adenocarcinoma cell line A549 were established and randomly divided into 3 groups when the maximum diameter
of tumor reached 1 cm: control, cisplatin (DDP) and cryoablation. The nude mice were sacrificed after 21-d
cryoablation to obtain the tumor tissues. Then immunohistochemistry was applied to determine MVD and the
expression of VEGF in tumor tissues. Results: The tumor volumes of control group, DDP group and cryoablation
group were 1.48±0.14 cm3, 1.03±0.12 cm3 and 0.99±0.06 cm3 respectively and the differences were significant
(P<0.01), whereas MVD values were 21.1±0.86, 24.7±0.72 and 29.2±0.96 (P<0.01) and the positive expression
rates of VEGF were 36.2±1.72%, 39.0±1.79% and 50.8±2.14% (P<0.01), respectively, showing that MVD was
proportional to the positive expression of VEGF (r=0.928, P<0.01). Conclusions: Cryoablation can effectively
inhibit tumor growth, but tumor angiogenesis significantly increases in residual tumors, with high expression
of VEGF playing an important role in the residual tumor angiogenesis.
Click here: http://www.apocpcontrol.org/paper_file/ ... a%20Ma.pdf
Tumor progression during healing study on mice
Non-ASPS articles which could be relevant.
Return to “Other Publications”
Jump to
- Welcome to CureASPS.org!
- ↳ Guest Book
- ↳ Forum Issues and Suggestions
- News and Updates
- ↳ Personal Stories and Updates
- ↳ Success Stories
- ↳ Rest In Peace
- ↳ Anonymous Patient Updates
- ↳ Chinese group news
- ↳ Medical Publications
- ↳ Other Publications
- ↳ Sarcoma Meetings and Conferences
- ASPS Clinical Trials
- ↳ Other Clinical Trials
- ↳ COMPLETED - ARQ 197 Clinical Trial
- ↳ COMPLETED - Dana Farber Vaccine Clinical Trial (GVAX)
- ↳ Dasatinib
- ↳ Alisertib
- ↳ Cediranib
- ↳ Anlotinib
- ↳ Immune checkpoint inhibitors (ICI)
- ↳ Axitinib and Pembrolizumab (Keytruda) in Miami, US
- ↳ TECENTRIQ (atezolizumab) by Genentech
- ↳ Pfizer's PF-06801591
- ↳ Durvalumab+Tremelimumab at MDACC
- Symptoms and Diagnostics
- ↳ Symptoms
- ↳ Scan Types and Follow-Up
- ↳ Molecular Studies
- ↳ Pathology results
- Primary Tumor Treatment
- ↳ Resection
- ↳ Treatment of Non-Resectable Primary Tumor
- ↳ Radiation
- Systemic Treatment
- ↳ TKI
- ↳ Sutent (sunitinib)
- ↳ Pazopanib
- ↳ Сabozantinib (Cometriq)
- ↳ Sorafenib
- ↳ Chemotherapy
- ↳ Metronomic chemotherapy
- ↳ Temozolomide (Temodar)
- ↳ Side effects of systemic treatments
- ↳ Interferon alpha
- ↳ Immune checkpoint inhibitors ICI (PD-1 and PD-L1 targeting drugs)
- ↳ Keytruda
- ↳ Opdivo
- ↳ TECENTRIQ (atezolizumab)
- ↳ Toxicity, problems and potentiation strategies
- ↳ Treatment response criteria and evaluation/scanning problems/rare cases
- ↳ treatment discontinuation/re-treatment
- Metastatic Disease Treatment
- ↳ Local treatment modalities
- ↳ cryoablation
- ↳ Side effects/complications of the local ablations
- ↳ Radiosurgery
- ↳ Microwave ablation
- ↳ High intensity focused ultrasound (HIFU)
- ↳ Lung Metastases
- ↳ Laser assisted surgery
- ↳ Brain Metastases
- ↳ Bone Metastases
- ↳ Other Metastases
- ↳ Abdominal Metastases
- ↳ Liver metastases
- ↳ Heart Metastases
- ↳ Spinal metastases
- ↳ Adrenal metastases
- ↳ Pancreatic metastases
- Living with ASPS
- ↳ Insurance Coverage
- ↳ Second opinion from a sarcoma center
- ↳ Finanical assistance
- ↳ Diet and lifestyle
- ↳ Related studies
- ↳ Pain management
- ↳ Travel assistance